Metastasis Inhibition Articles & Analysis

1 news found

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

PAD4 activity in tumor cells may play a significant role in cancer metastasis. The first-in-class mechanism of PAD4 inhibition reduces neutrophil extra-cellular traps (NETs) which stimulates cancer cell adhesion, migration and invasion. Therefore, inhibition of PAD4 could be a novel strategy to inhibit cancer progression and ...

Apr. 11, 2022

ByJubilant Therapeutics Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you